Hiraiwa, Hiroaki http://orcid.org/0000-0002-1606-7037
Okumura, Takahiro
Sawamura, Akinori
Araki, Takashi
Mizutani, Takashi
Kazama, Shingo
Kimura, Yuki
Shibata, Naoki
Oishi, Hideo
Kuwayama, Tasuku
Kondo, Toru
Furusawa, Kenji
Morimoto, Ryota
Murohara, Toyoaki
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP21K16085, JP19K17592)
Article History
Received: 6 October 2021
Accepted: 14 January 2022
First Online: 29 January 2022
Declarations
:
: TO received research grants from Ono Pharmaceutical Co. Ltd., Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharma Inc., and Amgen Astellas BioPharma KK outside of the submitted work. TO received honorariums from Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Novartis Pharma KK, and Medtronic Japan Co. Ltd. TM received lecture fees from Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kowa Co. Ltd., MSD KK, Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma KK, Pfizer Japan Inc., Sanofi-Aventis KK, and Takeda Pharmaceutical Co. Ltd. TM received an unrestricted research grant for the Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kowa Co. Ltd., MSD KK, Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma KK, Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis KK, Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. The remaining authors have no conflicts of interest relevant to this article to disclose.
: The study protocol complied with the Declaration of Helsinki, and the protocol was approved by the ethics review board of our institution.
: Written informed consent was obtained from all patients for participation.
: Written informed consent was obtained from all patients for publication of data.